Siqing fu
M.D. Anderson Cancer Center · University of Texas MD Anderson Cancer Center LAO · MD Anderson
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Siqing fu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:02 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06576037 · Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial OriginM.D. Anderson Cancer Center · recruiting · Solid Tumor · principal investigator
- Ph1NCT06365918 · Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With CarcinomatosisM.D. Anderson Cancer Center · withdrawn · Advanced Solid Tumor, Carcinomatosis · principal investigator
- Ph1NCT05431582 · Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid TumorsM.D. Anderson Cancer Center · withdrawn · Tumors, Ovarian Cancer, Breast Cancer · principal investigator
- Ph1NCT05300438 · Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.Tyligand Bioscience (Shanghai) Limited · unknown · Cancer (With or Without Metastasis) · principal investigator
- Ph1NCT05075993 · Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsM.D. Anderson Cancer Center · terminated · Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma · principal investigator
- Ph1NCT05038839 · Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm · principal investigator
- Ph2NCT05036681 · A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial CarcinomaM.D. Anderson Cancer Center · terminated · Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma · principal investigator
- Ph1/Ph2NCT04902040 · Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesM.D. Anderson Cancer Center · terminated · Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm · principal investigator
- Ph1NCT04711161 · First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.Green3Bio, Inc. · suspended · Ovarian Tumors · principal investigator
- Ph1NCT04192344 · A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid TumorAbbisko Therapeutics Co, Ltd · recruiting · Neoplasms, Tenosynovial Giant Cell Tumor · principal investigator
- Ph1NCT03784677 · A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma · principal investigator
- Ph1NCT03756818 · TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Malignant Solid Neoplasm, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm · principal investigator
- Ph2NCT03253679 · AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 AmplificationNational Cancer Institute (NCI) · completed · Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm · principal investigator
- Ph1NCT03203525 · Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic CancerM.D. Anderson Cancer Center · terminated · Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver · principal investigator
- Ph1NCT02812056 · Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated MalignanciesM.D. Anderson Cancer Center · withdrawn · Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Lip Oral Cavity and Pharynx · principal investigator
- Ph1NCT02042989 · MLN9708 and Vorinostat in Patients With Advanced p53 Mutant MalignanciesM.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT01948843 · Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast CancerPolaris Group · completed · HER2 Negative Metastatic Breast Cancer · principal investigator
- Ph1NCT01665183 · Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic MelanomaPolaris Group · completed · Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors · principal investigator
- Ph1NCT01339871 · Study of Pazopanib and Vorinostat in Patients With Advanced MalignanciesM.D. Anderson Cancer Center · completed · Advanced Cancer · principal investigator
- Ph1NCT01200004 · Study of Grifola Frondosa (Maitake), Azacitidine, and LenalidomideM.D. Anderson Cancer Center · terminated · Advanced Cancers · principal investigator
- Ph1NCT01178112 · Trientine and Carboplatin in Advanced MalignanciesM.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT00732836 · Hepatic Arterial Infusion (HAI) of AbraxaneM.D. Anderson Cancer Center · completed · Liver Cancer, Advanced Cancers, Solid Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT03756818, NCT03203525
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026Named on NCT03253679
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:02 UTC. The ranking covers the 200 most relevant of 310 PubMed records, and a shared surname and initials can bring in a namesake. All 310 on PubMed
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet · 20202,489 citationsRCR 131.1
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- 209 citationsRCR 5.4
- 192 citationsRCR 5.1
- 190 citationsRCR 5.4
- GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.Lancet Haematol · 2023146 citationsRCR 11.6
- Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.Clin Cancer Res · 2021141 citationsRCR 6.6
- Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.J Immunother Cancer · 2019131 citationsRCR 5.2
- Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.J Immunother Cancer · 2017125 citationsRCR 3.8
- Phase 2 study of pembrolizumab in patients with advanced rare cancers.J Immunother Cancer · 2020123 citationsRCR 5.7